Vireo Growth (VREOF) Cash & Equivalents Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Cash & Equivalents Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 29.96% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 20.41% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -2.73% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.02% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 3.22% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 52.71% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 36.93% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 10.41% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 137.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137.05% |
| Dec 31, 2025 | 100.72% |
| Sep 30, 2025 | 75.24% |
| Jun 30, 2025 | 80.10% |
| Mar 31, 2025 | 115.60% |
| Dec 31, 2024 | 82.16% |
| Sep 30, 2024 | -14.82% |
| Jun 30, 2024 | -18.61% |
| Mar 31, 2024 | -32.27% |
| Dec 31, 2023 | -16.18% |
| Sep 30, 2023 | -9.39% |
| Jun 30, 2023 | 15.73% |
| Mar 31, 2023 | -4.10% |